GSK Investigational Site

Donetsk 83114

0 studies enrolling now · 30 studies all time

What they study most

Acute Coronary Syndrome, Asthma, Atherosclerosis, Carcinoma, Hepatocellular, Crohn's Disease, Epilepsy, Partial, Hepatitis C, Chronic, Lung Cancer, Non-Small Cell, Melanoma, Pulmonary Disease, Chronic Obstructive, Purpura, Thrombocytopaenic, Idiopathic, Systemic Lupus Erythematosus

Studies at this site

• Belimumab Assessment of Safety in SLE — Completed
• MEA112997 Open-label Long Term Extension Safety Study of Mepolizumab in Asthmatic Subjects — Completed
• A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor — Stopped early
• GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer — Stopped early
• Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma — Completed
• SAS115359: A 6-month Study to Assess the Safety and Benefit of Inhaled Fluticasone Propionate/Salmeterol Combination Compared With Inhaled Fluticasone Propionate in the Treatment of Adolescents and Adults (12 Years of Age and Older) With Asthma. — Completed
• Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary Disease — Completed
• Fluticasone Furoate/GW642444 Inhalation Powder Long-Term Safety Study — Completed
• An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444.Study B — Completed
• Study Evaluating the 24-Hour Pulmonary Function Profile of Fluticasone Furoate (FF) /GW642444 (Vilanterol) (VI) Inhalation Powder 100/25mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD) — Completed
• Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-centre, Dose Ranging Study to Evaluate the Efficacy and Safety of Losmapimod Tablets Administered Twice Daily Compared With Placebo for 24 Weeks in Adult Subjects With Chronic Obstructive Pulmonary Disease (COPD). — Completed
• An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease — Stopped early
• A 24-week Evaluation of GSK573719/Vilanterol (125/25mcg) and Components in COPD — Completed
• Asthma Exacerbation Study — Completed
• Dose Ranging Efficacy And Safety With Mepolizumab in Severe Asthma — Completed
• 24-week Trial Comparing GSK573719/GW642444 With GW642444 and With Tiotropium in Chronic Obstructive Pulmonary Disease — Completed
• A Randomized Study To Evaluate The Efficacy And Safety Of An Investigational Drug In Adolescent And Adult Subjects With Persistent Asthma. — Completed
• A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol and Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD) — Completed
• Study B2C112060: A Study of the Efficacy and Safety of Vilanterol Inhalation Powder in Adults and Adolescents With Persistent Asthma — Completed
• Dose Ranging Study Evaluating the Efficacy and Safety of GSK2190915 Administered Once Daily — Completed
• Open-Label Extension Study of GSK1605786A — Stopped early
• GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease — Stopped early
• The Stabilization Of pLaques usIng Darapladib-Thrombolysis In Myocardial Infarction 52 Trial — Completed
• The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial — Completed
• SB-497115 (Oral Thrombopoietin Receptor Agonist) Versus Placebo In Adult Cancer Patients Receiving Chemotherapy — Completed
• LENS - Long-term Eltrombopag Observational Study — Completed
• Evaluation of COPD (Chronic Obstructive Pulmonary Disease) to Longitudinally Identify Predictive Surrogate Endpoints — Completed
• Conversion To Monotherapy With Lamictal Extended Release Tablets For Treatment Of Partial Epilepsy — Completed
• Eltrombopag To Initiate And Maintain Interferon Antiviral Treatment To Benefit Subjects With Hepatitis C Liver Disease — Completed
• Eltrombopag To Initiate And Maintain Interferon Antiviral Treatment To Subjects With Hepatitis C Related Liver Disease — Completed